

Operations of the Audit Committee

The Company has established an Audit Committee composed of three independent directors. Leveraging the independent directors' extensive industry experience, the Committee effectively fulfills its oversight and supervisory functions.

3.3.1.1 Key responsibilities and functions of the Audit Committee

The Company's Audit Committee is formed by all Independent Directors, one of whom is the convener. The operation of the Audit Committee is to supervise the proper presentation of the Company's financial statements, the selection (dismissal) and independence and performance of certified public accountants, and the effective implementation of the Company's internal control, as well as ensuring the Company's compliance with relevant laws and rules, and the management of the Company's existing or potential risks.

- (1) Preparation or revision of the internal control system as required by Article 14-1 of the Securities and Exchange Act.
- (2) Evaluation of the effectiveness of the internal control system.
- (3) Adoption or revision, pursuant to Article 36-1 of the Securities and Exchange Act, of any handling procedures for material financial or business transactions, such as the acquisition or disposal of assets, derivatives trading, loans of funds to others, and endorsements or guarantees for others.
- (4) Matters involving directors' own interests.
- (5) Asset transactions or derivatives trading of a material nature.
- (6) Material loans, endorsements, or provision of guarantees.
- (7) The offering, issuance, or private placement of equity-type securities.
- (8) The appointment, dismissal of CPAs, or their compensations.
- (9) The appointment or dismissal of a financial, accounting, or internal audit officer.
- (10) Annual financial statements that are required to be signed or sealed by the Chairman, manager, and Corporate Controller, and Q2 financial statements that are audited and certified by CPAs.
- (11) Other major matters stipulated by the company or the competent authority.

Operations of the Audit Committee

1. In 2025, the Audit Committee convened 8 meetings. The details of the attendance from the Independent Directors are as follows:

Title	Name	Attendance in Person	By Proxy	Actual attendance rate (%)	Remark
Independent Director	Tsai, Jin-Pau	2	-	100%	Resign on March 27, 2025
Independent Director	Wang, Tay-Chang	8	-	100%	Convener
Independent Director	Hsieh, Shang-Hsien	6	2	75%	-
Independent Director	Change, Chi-Feng	2	-	100%	Resign on March 27, 2025
Independent Director	Lai, Ming-Jung	-	-	-	Resign on April 2, 2025
Independent Director	Chang, Yen-Shu	6	-	100%	On board on March 27, 2025

2. Matters referred to in Article 14-5 of the Securities and Exchange Act: Please refer to "3.4.2.1 Important resolutions of the Audit Committee":

Audit Committee Meeting Date	Content of Proposal
4-6 2025/01/21	<ol style="list-style-type: none"> Proposal for the capital injection plan from the Company to the U.S. subsidiary, Tanvex BioPharma USA Inc. ("Tanvex USA") through a rights issuance up to US\$ 50,000,000 in 2025. Proposal for the capital investment plan in the U.S. subsidiary, Tanvex BioPharma USA Inc. Proposal for the revisions to the Company's Level of Authority Form.
4-7 2025/03/14	<ol style="list-style-type: none"> Proposal for the 2024 Internal Control Declaration be approved Proposal for FY2024 Business Report and Consolidated Financial Report be approved. Proposal for FY2024 deficit compensation. Proposal the appointment of CPA for the FY2025 consolidated financial statements audit.
5-1 2025/04/07	<ol style="list-style-type: none"> Proposal for new shares be issued through a cash capital increase for 2025, along with a revision of the Sound Business Plan.

Operations of the Audit Committee

Audit Committee Meeting Date	Content of Proposal
5-3 2025/06/27	2. Proposal for signing the License, Supply & Distribution Agreement between Tanvex BioPharma USA, Inc. and Invagen Pharmaceuticals Inc.
5-4 2025/08/12	1. Proposal for the establishment of “Internal Control System – General Rules”, “Operating Procedures for Internal Control Self-Assessment”, “Operating Procedures for Internal Audit”, and “Operating Procedures for Deputy and Delegation of Authority” for the Company. 2. Proposal for Q2’25 Consolidated Financial Report be approved.
5-5 2025/11/12	1. Proposal for the revision of “Purchase and Payment Cycle” and the establishment of “Rules Governing Financial and Business Matters Between Company and its Related Parties” for the Company.
5-6 2025/12/11	1. Proposal for the FY2026 audit plan. 2. Proposal for the capital injection plan from the Company to the U.S. subsidiary, Tanvex BioPharma USA, Inc. (“Tanvex USA”) through a rights issuance up to US\$45,000,000. 3. Proposal for the evaluation of the independence and qualifications of the CPA. 4. Proposal for the appointment of CPA for auditing the FY2026 consolidated financial statements of the Company.

3. Other matters that were not approved by the Audit Committee but were approved by two-thirds or more of all directors: None.